Axsome Therapeutics, Inc. (AXSM)

Market Cap	3.75B
Revenue (ttm)	251.02M
Net Income (ttm)	-296.38M
Shares Out	47.50M
EPS (ttm)	-6.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	409,721
Open	81.19
Previous Close	81.03
Day's Range	78.80 - 81.34
52-Week Range	55.02 - 98.40
Beta	1.25
Analysts	Strong Buy
Price Target	123.55 (+56.53%)
Earnings Date	Aug 5, 2024

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 545
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM

Financial Performance

In 2023, AXSM's revenue was $270.60 million, an increase of 440.80% compared to the previous year's $50.04 million. Losses were -$239.24 million, 27.8% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $123.55, which is an increase of 56.53% from the latest price.

Price Target

$123.55

(56.53% upside)

Analyst Consensus: Strong Buy